UY28323A1 - Compuestos inhibidores de la hepatitis c - Google Patents

Compuestos inhibidores de la hepatitis c

Info

Publication number
UY28323A1
UY28323A1 UY28323A UY28323A UY28323A1 UY 28323 A1 UY28323 A1 UY 28323A1 UY 28323 A UY28323 A UY 28323A UY 28323 A UY28323 A UY 28323A UY 28323 A1 UY28323 A1 UY 28323A1
Authority
UY
Uruguay
Prior art keywords
hepatitis
inhibiting compounds
compounds
hcv
protease
Prior art date
Application number
UY28323A
Other languages
English (en)
Spanish (es)
Inventor
Murray Douglas Bailey
Punit Bhardwaj
Josee Bordeleau
Pasquale Forgione
Elise Ghiro
Vida J Gorys
Nathalie Goudreau
Sylvie Goulet
Ted Halmos
Montse Llinas-Brunet
Jean Rancourt
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476973&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY28323(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY28323A1 publication Critical patent/UY28323A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
UY28323A 2003-05-21 2004-05-19 Compuestos inhibidores de la hepatitis c UY28323A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47270903P 2003-05-21 2003-05-21

Publications (1)

Publication Number Publication Date
UY28323A1 true UY28323A1 (es) 2004-12-31

Family

ID=33476973

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28323A UY28323A1 (es) 2003-05-21 2004-05-19 Compuestos inhibidores de la hepatitis c

Country Status (33)

Country Link
US (5) US7585845B2 (US08067438-20111129-C00609.png)
EP (1) EP1654261B1 (US08067438-20111129-C00609.png)
JP (2) JP4447603B2 (US08067438-20111129-C00609.png)
KR (1) KR101115294B1 (US08067438-20111129-C00609.png)
CN (3) CN103204903A (US08067438-20111129-C00609.png)
AT (1) ATE378334T1 (US08067438-20111129-C00609.png)
AU (1) AU2004240704B9 (US08067438-20111129-C00609.png)
BR (1) BRPI0410456B8 (US08067438-20111129-C00609.png)
CA (1) CA2522577C (US08067438-20111129-C00609.png)
CL (1) CL2004001161A1 (US08067438-20111129-C00609.png)
CO (1) CO5630024A2 (US08067438-20111129-C00609.png)
CY (1) CY1107200T1 (US08067438-20111129-C00609.png)
DE (1) DE602004010137T2 (US08067438-20111129-C00609.png)
DK (1) DK1654261T3 (US08067438-20111129-C00609.png)
EA (1) EA009295B1 (US08067438-20111129-C00609.png)
EC (1) ECSP056181A (US08067438-20111129-C00609.png)
ES (1) ES2297424T3 (US08067438-20111129-C00609.png)
HR (1) HRP20080014T3 (US08067438-20111129-C00609.png)
IL (1) IL172013A (US08067438-20111129-C00609.png)
ME (1) MEP58308A (US08067438-20111129-C00609.png)
MX (1) MXPA05012545A (US08067438-20111129-C00609.png)
MY (1) MY143076A (US08067438-20111129-C00609.png)
NO (1) NO332056B1 (US08067438-20111129-C00609.png)
NZ (1) NZ544076A (US08067438-20111129-C00609.png)
PE (1) PE20050204A1 (US08067438-20111129-C00609.png)
PL (1) PL1654261T3 (US08067438-20111129-C00609.png)
PT (1) PT1654261E (US08067438-20111129-C00609.png)
RS (1) RS51294B (US08067438-20111129-C00609.png)
TW (1) TWI327145B (US08067438-20111129-C00609.png)
UA (1) UA83046C2 (US08067438-20111129-C00609.png)
UY (1) UY28323A1 (US08067438-20111129-C00609.png)
WO (1) WO2004103996A1 (US08067438-20111129-C00609.png)
ZA (1) ZA200508201B (US08067438-20111129-C00609.png)

Families Citing this family (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA979327B (en) 1996-10-18 1998-05-11 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease.
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US7119072B2 (en) * 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
NZ544076A (en) * 2003-05-21 2009-04-30 Boehringer Ingelheim Int Hepatitis C inhibitor compounds
UY28500A1 (es) 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
KR20060094083A (ko) * 2003-09-22 2006-08-28 베링거 인겔하임 인터내셔날 게엠베하 Ｃ형 간염 바이러스에 대해 활성인 마크로사이클릭펩타이드
JP2007532474A (ja) * 2003-10-10 2007-11-15 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特にｈｃｖのｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
US7132504B2 (en) * 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DE602005025855D1 (de) * 2004-01-21 2011-02-24 Boehringer Ingelheim Pharma Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
RS51243B (sr) 2004-01-30 2010-12-31 Medivir Ab. Inhibitori ns-3 serina hcv proteaze
KR101320907B1 (ko) 2004-02-20 2013-10-22 베링거 인겔하임 인터내셔날 게엠베하 바이러스 폴리머라제 억제제
RU2006136084A (ru) 2004-03-15 2008-04-27 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Способ получения микроциклических соединений
EP1753775B1 (en) 2004-05-25 2012-12-26 Boehringer Ingelheim International GmbH Process for preparing acyclic hcv protease inhibitors
CA2556669C (en) * 2004-06-28 2012-05-01 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
UY29016A1 (es) * 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
CA2573346C (en) 2004-07-20 2011-09-20 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
MX2007003812A (es) * 2004-10-01 2007-05-24 Vertex Pharma Inhibicion de proteasa ns3-ns4a del virus de la hepatitis c (vhc).
TW201424733A (zh) 2004-10-29 2014-07-01 Vertex Pharma 劑量型式
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2332963A3 (en) * 2005-03-08 2011-11-16 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic compounds
US7879797B2 (en) 2005-05-02 2011-02-01 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI449711B (zh) * 2005-06-30 2014-08-21 Virobay Inc Ｃ型肝炎病毒（ｈｃｖ）抑制劑
US7608592B2 (en) * 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI389908B (zh) 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
US7470664B2 (en) * 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
JP4705984B2 (ja) 2005-08-01 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｃｖｎｓ３プロテアーゼ阻害剤としての大環状ペプチド
CA2617679A1 (en) * 2005-08-02 2007-02-08 Steve Lyons Inhibitors of serine proteases
WO2007019674A1 (en) 2005-08-12 2007-02-22 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP1945605B1 (en) * 2005-11-03 2013-01-09 Boehringer Ingelheim International Gmbh Process for preparing substituted anisidines
WO2007130704A1 (en) * 2006-01-25 2007-11-15 Boehringer Ingelheim International Gmbh A two step process for preparing substituted anisidines
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
AU2007217355B2 (en) 2006-02-27 2012-06-21 Vertex Pharmaceuticals Incorporated Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same
AU2007227544B2 (en) * 2006-03-16 2012-11-01 Vertex Pharmaceuticals Incorporated Deuterated hepatitis C protease inhibitors
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
EP2049474B1 (en) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
JP5517614B2 (ja) 2006-07-13 2014-06-11 アキリオン ファーマシューティカルズ，インコーポレーテッド ウイルス複製阻害剤としての４−アミノ−４−オキソブタノイルペプチド類
US7718612B2 (en) * 2007-08-02 2010-05-18 Enanta Pharmaceuticals, Inc. Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
BRPI0716060A2 (pt) 2006-08-17 2013-09-17 Boehringer Ingelheim Int inibidores de polimerase viral.
CA2667266C (en) 2006-10-24 2015-11-24 Merck & Co., Inc. Hcv ns3 protease inhibitors
EP2079479B1 (en) 2006-10-24 2014-11-26 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
AU2007309546A1 (en) 2006-10-24 2008-05-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HCV NS3 protease inhibitors
US20100099695A1 (en) * 2006-10-27 2010-04-22 Liverton Nigel J HCV NS3 Protease Inhibitors
US8377874B2 (en) 2006-10-27 2013-02-19 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008070358A2 (en) * 2006-11-16 2008-06-12 Phenomix Corporation N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2121707B1 (en) 2006-12-20 2012-12-05 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Antiviral indoles
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2679377A1 (en) 2007-02-26 2008-09-04 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of hcv replication
TW200846343A (en) * 2007-02-27 2008-12-01 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same
JP2010519329A (ja) * 2007-02-27 2010-06-03 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ阻害剤
BRPI0813733A2 (pt) 2007-06-29 2019-11-05 Gilead Sciences Inc composto com atividade inibidora de hcv, sua composição farmacêutica e seu uso.
CA2691442C (en) 2007-06-29 2014-01-21 Gilead Sciences, Inc. Antiviral compounds
CA2693537C (en) 2007-07-17 2013-06-25 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis c infections
US8927569B2 (en) 2007-07-19 2015-01-06 Merck Sharp & Dohme Corp. Macrocyclic compounds as antiviral agents
CA2693997C (en) 2007-08-03 2013-01-15 Pierre L. Beaulieu Viral polymerase inhibitors
US8492546B2 (en) * 2007-08-30 2013-07-23 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
EP2190858A4 (en) 2007-09-24 2013-02-13 Achillion Pharmaceuticals Inc PEPTIDES CONTAINING UREA AS INHIBITORS OF VIRAL REPLICATION
EP2224942A4 (en) 2007-12-05 2012-01-25 Enanta Pharm Inc FLUORATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS
CA2708042A1 (en) * 2007-12-05 2009-06-11 Enanta Pharmaceuticals, Inc. Quinoxalinyl derivatives
MX2010006313A (es) 2007-12-19 2010-06-25 Boehringer Ingelheim Int Inhibidores de la polimerasa virica.
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
WO2009082701A1 (en) 2007-12-21 2009-07-02 Avila Therapeutics, Inc. Hcv protease inhibitors and uses thereof
CN101951770B (zh) 2007-12-21 2014-12-31 阿维拉制药公司 Hcv蛋白酶抑制剂和其用途
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
KR20100118991A (ko) * 2008-02-04 2010-11-08 아이데닉스 파마슈티칼스, 인코포레이티드 매크로시클릭 세린 프로테아제 억제제
JP5608563B2 (ja) * 2008-02-25 2014-10-15 メルク・シャープ・アンド・ドーム・コーポレーション 治療用化合物
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009134624A1 (en) 2008-04-28 2009-11-05 Merck & Co., Inc. Hcv ns3 protease inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009148923A1 (en) 2008-05-29 2009-12-10 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
DK2310095T3 (da) 2008-07-22 2012-12-10 Merck Sharp & Dohme Makrocykliske quinoxalinforbindelser som hcv-ns3-protease-inhibitorer
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
AU2014201788B2 (en) * 2008-09-16 2015-09-03 Boehringer Ingelheim International Gmbh Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor
SI2331538T1 (sl) * 2008-09-16 2014-06-30 Boehringer Ingelheim International Gmbh Kristalinične oblike 2-tiazolil-4-kinolinil-oksi derivata, učinkovitega inhibitorja HCV
WO2010033443A1 (en) 2008-09-17 2010-03-25 Boehringer Ingelheim International Gmbh Combination of hcv ns3 protease inhibitor with interferon and ribavirin
CA2737958A1 (en) * 2008-09-23 2010-04-01 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102223875A (zh) * 2008-11-21 2011-10-19 贝林格尔.英格海姆国际有限公司 口服给药的强效hcv抑制剂的药物组合物
DK2364309T3 (en) 2008-12-10 2015-01-12 Achillion Pharmaceuticals Inc NEW 4-AMINO-4-OXOBUTANOYLPEPTIDER as inhibitors of viral replication
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2009335904A1 (en) 2008-12-19 2011-08-04 Gilead Sciences, Inc. HCV NS3 protease inhibitors
JP2012514605A (ja) 2009-01-07 2012-06-28 サイネクシス，インコーポレーテッド Ｈｃｖおよびｈｉｖ感染の治療への使用におけるシクロスポリン誘導体
JP2012517478A (ja) 2009-02-12 2012-08-02 バーテックス ファーマシューティカルズ インコーポレイテッド ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、ｈｃｖ組合せ治療剤
JP2012520891A (ja) 2009-03-19 2012-09-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング スルホニルキノリンの製造方法
TR201109333T1 (tr) * 2009-03-26 2012-01-23 Daewoong Pharmaceutical Co. Ltd. Adefovir dipivoksilin yeni kristal formları ve bunların hazırlama işlemleri.
JP2012523419A (ja) 2009-04-08 2012-10-04 イデニク プハルマセウティカルス，インコーポレイテッド 大環状セリンプロテアーゼ阻害剤
EP2427434B1 (en) 2009-05-05 2017-05-31 Boehringer Ingelheim International GmbH Process for preparing bromo-substituted quinolines
WO2010132163A1 (en) 2009-05-13 2010-11-18 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis c virus inhibitors
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
MX2011013824A (es) * 2009-07-07 2012-01-30 Boehringer Ingelheim Int Composicion farmaceutica para un inhibidor de proteasa del virus de la hepatitis c.
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
CA2769652A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
US8324417B2 (en) 2009-08-19 2012-12-04 Virobay, Inc. Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
WO2011049908A2 (en) * 2009-10-19 2011-04-28 Enanta Pharmaceuticals, Inc. Bismacrokyclic compounds as hepatitis c virus inhibitors
CN102596201A (zh) 2009-10-30 2012-07-18 贝林格尔.英格海姆国际有限公司 包含BI201335、干扰素α和利巴韦林的HCV组合治疗的用药方案
EA201200890A1 (ru) * 2009-12-18 2013-01-30 Бёрингер Ингельхайм Интернациональ Гмбх Комбинированная терапия hcv
MX2012008652A (es) 2010-01-29 2012-08-23 Vertex Pharma Terapias para tratar infeccion por virus de hepatitis c.
US8530497B2 (en) * 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
TW201208704A (en) 2010-07-14 2012-03-01 Vertex Pharma Palatable pharmaceutical composition
PT2618831E (pt) 2010-09-21 2016-03-04 Enanta Pharm Inc Inibidores de serina-protease do vhc derivados de prolina macrocíclica
WO2012041771A1 (en) 2010-09-30 2012-04-05 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection
US9011833B2 (en) * 2010-10-08 2015-04-21 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
US10873190B2 (en) 2010-11-19 2020-12-22 Tseng-Lu Chien Desktop or floor LED lighting device has USB-port(s)
US10873191B2 (en) 2010-11-19 2020-12-22 Tseng-Lu Chien Desk top alarm or time or LED lighting device has USB-port(s)
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
SG191759A1 (en) 2010-12-30 2013-08-30 Enanta Pharm Inc Phenanthridine macrocyclic hepatitis c serine protease inhibitors
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
WO2012109646A1 (en) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Treatment of hcv in hiv infection patients
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8912141B2 (en) 2011-06-23 2014-12-16 Panmed Ltd. Treatment of hepatitis C virus
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
JP5677645B2 (ja) 2011-10-21 2015-02-25 アッヴィ・インコーポレイテッド 少なくとも２種の直接作用型抗ウイルス剤、およびリバビリンを含むがインターフェロンを含まない、ｈｃｖを治療するための方法
CN104436197A (zh) 2011-10-21 2015-03-25 艾伯维公司 至少两种直接作用抗病毒剂的组合产品
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
AU2013208024A1 (en) 2012-01-12 2014-07-10 Boehringer Ingelheim International Gmbh Stabilized pharmaceutical formulations of a potent HCV inhibitor
US20130195797A1 (en) 2012-01-31 2013-08-01 Vertex Pharmaceuticals Incorporated High potency formulations of vx-950
JP2015509980A (ja) 2012-03-14 2015-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法
WO2013147749A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient subgenotype populations
WO2013147750A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
JP2015512900A (ja) 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
JP5870001B2 (ja) 2012-09-28 2016-02-24 株式会社吉野工業所 ブロー成形装置及び容器の製造方法
BR112015007879A2 (pt) 2012-10-19 2017-07-04 Bristol Myers Squibb Co inibidores do vírus da hepatite c
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
UY35212A (es) * 2012-12-21 2014-06-30 Gilead Sciences Inc Inhibidores de la quinasa que regula la señal de la apoptosis
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
EP2970195B1 (en) 2013-03-14 2017-08-02 Achillion Pharmaceuticals, Inc. Processes for producing sovaprevir
WO2014145600A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
WO2014145507A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
JP6130585B2 (ja) 2013-03-15 2017-05-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 無定形状態のｈｃｖ阻害薬の固体経口投薬製剤
CA2902569A1 (en) 2013-03-15 2014-09-18 Gilead Sciences, Inc. Inhibitors of hepatitis c virus
EP2970192A1 (en) 2013-03-15 2016-01-20 Achillion Pharmaceuticals, Inc. Sovaprevir polymorphs and methods of manufacture thereof
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN106573926A (zh) * 2014-06-12 2017-04-19 美国卫生和人力服务部 杂环化合物及其使用方法
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF
CN108610301B (zh) * 2016-12-12 2021-08-31 中山大学 一类手性芳杂胺类衍生物及其合成方法和应用

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US684806A (en) * 1900-03-08 1901-10-22 Filter & Brautechnische Maschinen Fabrik Akt Ges Vorm L A Enzinger Pressure-regulator for pumps.
AR205953A1 (es) * 1975-01-22 1976-06-15 Diamond Shamrock Corp Produccion de carbonatos de metales a calinos en una celula de membrana
EP0124317B1 (en) 1983-04-27 1990-04-11 Ici Americas Inc. Proline derivatives
JPH01103993A (ja) 1987-10-16 1989-04-21 Sumitomo Electric Ind Ltd ダイヤモンド単結晶成長方法
JPH01135478A (ja) 1987-11-19 1989-05-29 Brother Ind Ltd 研削工具
US5164402A (en) 1989-08-16 1992-11-17 Pfizer Inc Azabicyclo quinolone and naphthyridinone carboxylic acids
US5290405A (en) * 1991-05-24 1994-03-01 Ceramatec, Inc. NaOH production from ceramic electrolytic cell
JPH05155827A (ja) 1991-12-09 1993-06-22 Banyu Pharmaceut Co Ltd ｃｉｓ−２−アミノシクロプロパンカルボン酸誘導体の製造法
PT804465E (pt) 1994-06-02 2003-12-31 Aventis Pharma Inc Novos inibidores da elastase
DE4430601A1 (de) 1994-08-22 1996-02-29 Beiersdorf Ag Zelladhäsions-Peptide zur Modifikation des Haftungsverhaltens eukaryontischer Zellen untereinander
US6159938A (en) 1994-11-21 2000-12-12 Cortech, Inc. Serine protease inhibitors comprising α-keto heterocycles
DE4444893A1 (de) 1994-12-16 1996-06-20 Merck Patent Gmbh Peptide und synthetische Zellmembranen
GB9517022D0 (en) 1995-08-19 1995-10-25 Glaxo Group Ltd Medicaments
DE19600034C2 (de) 1996-01-02 2003-12-24 Degussa 1,1,2-Trisubstituierte Cyclopropanverbindungen, Verfahren zu deren Herstellung und Dihydroxyethyl-substituierte 1-Amino-cyclopropan-1-carbonsäure
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
EP0907659A1 (en) 1996-05-10 1999-04-14 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
ZA979327B (en) 1996-10-18 1998-05-11 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease.
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
AU7127298A (en) 1997-04-14 1998-11-11 Emory University Serine protease inhibitors
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
JPH10298151A (ja) 1997-04-30 1998-11-10 Japan Energy Corp Ｃ型肝炎ウイルスプロテアーゼ阻害剤
WO1998053814A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
JPH1135478A (ja) 1997-07-17 1999-02-09 Soyaku Gijutsu Kenkyusho:Kk キク科植物の有機抽出物を含有する抗ｃ型肝炎ウイルス剤及びプロテアーゼｎｓ３の特異的阻害剤
NZ503262A (en) 1997-08-11 2002-10-25 Boehringer Ingelheim Ca Ltd Hepatitis C NS3 protease inhibitor peptides and peptide analogues
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
DE69827956T2 (de) 1997-08-11 2005-04-14 Boehringer Ingelheim (Canada) Ltd., Laval Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
JPH11127861A (ja) 1997-10-29 1999-05-18 Japan Energy Corp Ｃ型肝炎ウイルス由来のセリンプロテアーゼに対する中和抗体部分ペプチド
JP3612551B2 (ja) 1997-11-07 2005-01-19 独立行政法人産業技術総合研究所 Ｃ型肝炎ウイルスのｎｓ３プロテアーゼを阻害するｒｎａ分子
SE9704543D0 (sv) 1997-12-05 1997-12-05 Astra Ab New compounds
IT1299134B1 (it) 1998-02-02 2000-02-29 Angeletti P Ist Richerche Bio Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
ES2281170T3 (es) 1998-03-31 2007-09-16 Vertex Pharmaceuticals Incorporated Inhibidores de serina proteasas, particularmente proteasa ns3 del virus de la hepatitis c.
JPH11292840A (ja) 1998-04-06 1999-10-26 Soyaku Gijutsu Kenkyusho:Kk ノルスタチン誘導体又はその塩
US6455571B1 (en) 1998-04-23 2002-09-24 Abbott Laboratories Inhibitors of neuraminidases
GB9809664D0 (en) 1998-05-06 1998-07-01 Hoffmann La Roche a-Ketoamide derivatives
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
WO2000020400A1 (en) 1998-10-05 2000-04-13 Axys Pharmaceuticals, Inc. Novel compounds and compositions for treating hepatitis c infections
US6277830B1 (en) 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
GB9825946D0 (en) 1998-11-26 1999-01-20 Angeletti P Ist Richerche Bio Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
AU5920400A (en) 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Cell-based assay systems for examining hcv ns3 protease activity
EP1206449A1 (en) 1999-07-26 2002-05-22 Bristol-Myers Squibb Company Lactam inhibitors of hepatitis c virus ns3 protease
AU7511800A (en) 1999-08-30 2001-03-26 K.U. Leuven Research And Development Novel target for antiparasitic agents and inhibitors thereof
JP2001103993A (ja) 1999-10-05 2001-04-17 Japan Energy Corp 環状ペプチド及びセリンプロテアーゼ阻害剤
US6222241B1 (en) * 1999-10-29 2001-04-24 Advanced Micro Devices, Inc. Method and system for reducing ARC layer removal by providing a capping layer for the ARC layer
GB9925955D0 (en) 1999-11-02 1999-12-29 Angeletti P Ist Richerche Bio Hcv n33 protease inhibitors
US6774212B2 (en) 1999-12-03 2004-08-10 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease
AU2001234837A1 (en) 2000-02-08 2001-08-20 Schering Corporation Azapeptides useful in the treatment of hepatitis c
EP1261611A2 (en) 2000-02-29 2002-12-04 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
ES2240446T3 (es) 2000-04-03 2005-10-16 Vertex Pharma Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
EP1268525B1 (en) 2000-04-05 2008-12-31 Schering Corporation Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
AR030558A1 (es) 2000-04-19 2003-08-27 Schering Corp COMPUESTOS MACROCICLICOS, QUE INCLUYEN ENANTIOMEROS, ESTEROISOMEROS, ROTAMEROS Y TAUTOMEROS, SALES Y SOLVATOS FARMACEUTICAMENTE ACEPTABLES, COMPOSICIoN FARMACEUTICA, UN METODO PARA SU PREPARACION Y EL USO DE DICHOS COMPUESTOS PARA LA ELABORACION DE UN MEDICAMENTO, INHIBIDORES DE LA SERINA PROTEASA,
WO2002008251A2 (en) 2000-07-21 2002-01-31 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
HU229997B1 (en) 2000-07-21 2015-04-28 Dendreon Corp San Diego Peptides as ns3-serine protease inhibitors of hepatitis c virus
HUP0303358A3 (en) 2000-07-21 2005-10-28 Schering Corp Novel peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
WO2002060926A2 (en) 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
GB0107924D0 (en) 2001-03-29 2001-05-23 Angeletti P Ist Richerche Bio Inhibitor of hepatitis C virus NS3 protease
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2474156C (en) 2002-02-01 2011-09-20 Boehringer Ingelheim International Gmbh Tripeptides having a hydroxyproline ether of a substituted quinoline for the inhibition of ns3 (hepatitis c)
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) * 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
ES2350201T3 (es) 2002-05-20 2011-01-20 Bristol-Myers Squibb Company Sulfamidas heterocíclicas como inhibidores del virus de la hepatitis c.
PL213029B1 (pl) 2002-05-20 2012-12-31 Bristol Myers Squibb Co Podstawiona pochodna cykloalkilowa, zawierajaca ja kompozycja oraz ich zastosowanie
ATE503764T1 (de) 2002-05-20 2011-04-15 Bristol Myers Squibb Co Inhibitoren des hepatitis-c-virus
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20040033959A1 (en) 2002-07-19 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis C viral protease inhibitors
CA2516016C (en) 2003-03-05 2012-05-29 Boehringer Ingelheim International Gmbh Hepatitis c inhibiting compounds
EP1599496B1 (en) 2003-03-05 2010-11-03 Boehringer Ingelheim International GmbH Hepatitis c inhibitor peptide analogs
NZ544076A (en) * 2003-05-21 2009-04-30 Boehringer Ingelheim Int Hepatitis C inhibitor compounds
KR20060094083A (ko) 2003-09-22 2006-08-28 베링거 인겔하임 인터내셔날 게엠베하 Ｃ형 간염 바이러스에 대해 활성인 마크로사이클릭펩타이드
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2005059205A2 (en) * 2003-12-11 2005-06-30 American Pacific Corporation Electrolytic method to make alkali alcoholates using ceramic ion conducting solid membranes
RS51243B (sr) * 2004-01-30 2010-12-31 Medivir Ab. Inhibitori ns-3 serina hcv proteaze
EP1753775B1 (en) 2004-05-25 2012-12-26 Boehringer Ingelheim International GmbH Process for preparing acyclic hcv protease inhibitors
RU2004119195A (ru) 2004-06-24 2005-12-10 Дмитрий Александрович Гертнер (RU) Способ бесконтактной, гарантированной доставки товаров до конечного потребителя и система для его реализации
CA2556669C (en) 2004-06-28 2012-05-01 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
CA2573346C (en) 2004-07-20 2011-09-20 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
JP2010523821A (ja) * 2007-04-03 2010-07-15 セラマテック・インク イオン伝導固体セラミック膜を使用した水性アルカリ化学品のリサイクルのための電気化学的プロセス
US20090090638A1 (en) * 2007-10-05 2009-04-09 Kelly Michael T Processes and reactors for alkali metal production
US8246863B2 (en) * 2009-06-26 2012-08-21 Ceramatec, Inc. Alkali metal super ionic conducting ceramic

Also Published As

Publication number Publication date
CN103203010A (zh) 2013-07-17
EA009295B1 (ru) 2007-12-28
EP1654261A1 (en) 2006-05-10
PL1654261T3 (pl) 2008-04-30
BRPI0410456B1 (pt) 2019-07-09
DE602004010137D1 (de) 2007-12-27
BRPI0410456B8 (pt) 2021-05-25
ATE378334T1 (de) 2007-11-15
IL172013A (en) 2011-10-31
ZA200508201B (en) 2007-02-28
US7585845B2 (en) 2009-09-08
ME00382B (me) 2011-05-10
AU2004240704B9 (en) 2009-10-22
CA2522577A1 (en) 2004-12-02
DE602004010137T2 (de) 2008-09-11
KR20060013671A (ko) 2006-02-13
NO20056047L (no) 2006-01-31
US20050020503A1 (en) 2005-01-27
US20070243166A1 (en) 2007-10-18
DK1654261T3 (da) 2008-01-14
EA200501689A1 (ru) 2006-06-30
PE20050204A1 (es) 2005-05-04
TW200508220A (en) 2005-03-01
TWI327145B (en) 2010-07-11
WO2004103996A1 (en) 2004-12-02
CO5630024A2 (es) 2006-04-28
JP2006528937A (ja) 2006-12-28
MXPA05012545A (es) 2006-02-08
BRPI0410456A (pt) 2006-06-06
CA2522577C (en) 2011-04-26
UA83046C2 (ru) 2008-06-10
JP4447603B2 (ja) 2010-04-07
CN103204903A (zh) 2013-07-17
CL2004001161A1 (es) 2005-04-08
MY143076A (en) 2011-02-28
NO332056B1 (no) 2012-06-11
US20120034187A1 (en) 2012-02-09
JP2010043129A (ja) 2010-02-25
RS51294B (sr) 2010-12-31
AU2004240704B2 (en) 2009-08-20
HRP20080014T3 (en) 2008-02-29
NZ544076A (en) 2009-04-30
KR101115294B1 (ko) 2012-04-12
PT1654261E (pt) 2008-01-18
ES2297424T3 (es) 2008-05-01
AU2004240704A1 (en) 2004-12-02
US8067438B2 (en) 2011-11-29
US20110177030A1 (en) 2011-07-21
MEP58308A (en) 2011-05-10
CY1107200T1 (el) 2012-11-21
EP1654261B1 (en) 2007-11-14
CN1791599A (zh) 2006-06-21
ECSP056181A (es) 2006-04-19
RS20050871A (en) 2007-08-03
US20120269769A1 (en) 2012-10-25
US7939667B2 (en) 2011-05-10

Similar Documents

Publication Publication Date Title
CO5630024A2 (es) Compuestos inhibidores de la hepatitis c
TW200518746A (en) Novel inhibitors of hepatitis C virus NS3/NS4A serine protease
TW200615275A (en) Hepatitis C inhibitor dipeptide analogs
EP1771454A4 (en) PEPTIDE ANALOGUE AS HEPATITIS C HEMMER
SG164376A1 (en) Hcv ns3 protease inhibitors
ES2240446T3 (es) Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
RS20060197A (en) Macrocyclic peptides active against the hepatitis c virus
MY164469A (en) Hcv ns3 protease inhibitors
MX2009008872A (es) Compuestos macrociclicos como inhibidores de proteasa ns3 del virus de hepatitis c.
ATE486889T1 (de) Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
WO2006119061A3 (en) Hcv ns3 protease inhibitors
EA201170241A1 (ru) Макроциклические хиноксалиновые соединения в качестве ингибиторов протеазы вгс ns3
BR0305259A (pt) Inibidores de hcv ns5b polimerase
ATE498398T1 (de) Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus
UA90909C2 (en) Hcv ns3 protease inhibitors
ATE491706T1 (de) Heterocyclische antivirale verbindungen
WO2003051910A3 (en) Inhibitors of hepatitis c virus protease

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20171005